BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omani and Jeanie Carson Named Inaugural Departure Day Dove 1 for 2026 Special Olympics Airlift, Donating Aircraft and Crew to Lead Athletes Home26.2.2026 17:00:00 CET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that Omani and Jeanie Carson, of Omaha, Nebraska, have been named the inaugural departure day Dove 1 for the 2026 Special Olympics Airlift. The Carsons will donate their aircraft and crew to lead athletes home at the conclusion of the Games, marking the first year this honorary departure day distinction has been established. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226250477/en/ Omani and Jeanie Carson named inaugural departure day Dove 1 for 2026 Special Olympics Airlift, donating aircraft and crew to lead athletes home (Photo credit: Textron Aviation). As departure day Dove 1, the Carsons will guide the first aircraft lifting off from Minneapolis’ Twin Cities on Saturday, June 27, reuniting athletes with their families, hometowns and communities after a week of competition, determination and unforgettable experiences. This newly established
Loomis Sayles Euro Credit Team Celebrates Five-Year Milestones26.2.2026 17:00:00 CET | Press release
Loomis, Sayles & Company, the century-old investment manager with €363.8 billion in assets under management, celebrates the five-year anniversaries of its Loomis Sayles Euro Credit and Loomis Sayles Euro High Yield strategies. The Loomis Sayles Euro Credit Team, led by Co-Heads and Portfolio Managers Rik den Hartog and Pim van Mourik Broekman, manages €3.5 billion in assets across three strategies. Backed by Loomis Sayles’ industry-leading technology infrastructure and focused investment culture, the Euro Credit team seeks to generate consistent excess return versus the benchmark. The team believes this can be accomplished by using an active, conservative alpha investment process that aims to capitalize on inefficiencies in the euro credit market. Loomis Sayles Euro Credit invests primarily in investment grade, euro-denominated corporate bonds while Loomis Sayles Euro High Yield invests primarily in the BB segment of the euro-denominated high yield corporate bond market. The team’s Loo
Andersen Global udvider sine kompetencer i Canada med tilføjelsen af advokatfirmaet Parlee McLaws26.2.2026 16:21:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Canada med tilføjelsen af samarbejdsfirmaet Parlee McLaws LLP og styrker dermed sin eksisterende platform i landet med supplerende juridiske kompetencer. Parlee McLaws blev grundlagt i 1883 og tilbyder en bred vifte af juridiske ydelser, herunder selskabs- og erhvervsret, værdipapirret, retssager og tvistløsning, fast ejendom, arbejds- og ansættelsesret, immaterialret, energi, insolvens, forvaltningsret samt online brandbeskyttelse. Med sine i Edmonton og Calgary har firmaet opbygget et solidt ry for at levere praktiske, klientfokuserede løsninger, der er skræddersyet til behovene hos virksomheder og enkeltpersoner på tværs af brancher. "Vores samarbejde med Andersen Global giver vores klienter adgang til et bredere udvalg af globale ressourcer, samtidig med at vi fastholder den personlige service og dybe regionale indsigt, der kendetegner vores firma," udtaler Jerri L. Cairns, som er administrerende direktør i Parlee McLaws. "Vi ser frem t
Sitetracker Closes 2025 with Strong Momentum, Product Expansion, and a Clear Path into 202626.2.2026 15:00:00 CET | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced strong year-end results for 2025, marked by continued customer growth, expansion into new infrastructure markets, and major product innovations across operations, maintenance, and financial management. As infrastructure owners and operators face growing pressure to scale without adding headcount, Sitetracker enters 2026 positioned to help customers operate smarter, move faster, and unlock greater productivity. 2025 Highlights In 2025, Sitetracker delivered another year of growth and execution across its global customer base: Customer growth and market expansion: Sitetracker now serves more than 400 customers globally, supporting organizations across digital infrastructure, renewables, EV charging, utilities, and emerging infrastructure markets including data centers. Enhanced Operations & Maintenance capabilities: Sitetracker now connects field operations and work order ma
New Lenovo Service Delivers Always-On Infrastructure: Premier Support Plus for Servers Powered by Proactive, AI-Driven Support26.2.2026 15:00:00 CET | Press release
Lenovo today announced the availability of Lenovo Premier Support Plus for Servers, a new premium support offering designed to help enterprises reduce downtime, simplify IT operations, and keep mission-critical infrastructure always ready. Built for today’s always-on environments, Premier Support Plus combines AI-driven proactive and predictive support, preventative maintenance, 24/7 access to Lenovo experts, and designated Service Engagement Managers to help organizations move from reactive issue resolution to proactive system care. As digital operations continue to expand and infrastructure environments grow more complex, IT teams are under increasing pressure to maintain uptime while managing limited resources. Traditional, reactive support models can lead to extended outages, repeated issues, and unpredictable costs. Lenovo Premier Support Plus for Servers addresses these challenges by identifying potential issues early and resolving them before they impact business operations. “Wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom